PMID- 15017583
OWN - NLM
STAT- MEDLINE
DCOM- 20040414
LR  - 20190722
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 35
IP  - 3
DP  - 2004 Mar
TI  - Use of interphase fluorescence in situ hybridization in prostate needle biopsy 
      specimens with isolated high-grade prostatic intraepithelial neoplasia as a 
      predictor of prostate adenocarcinoma on follow-up biopsy.
PG  - 281-9
AB  - Isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on needle biopsy 
      confers an increased risk of prostate carcinoma (CaP) on follow-up biopsy. The 
      aim of this study is to determine whether paraffin-section fluorescence in situ 
      hybridization (FISH) of specific chromosome/oncogene copy number abnormalities 
      (CNAs) in biopsy specimens with isolated HGPIN increases the predictive value for 
      CaP on repeat biopsy. Cases were divided into 3 groups: controls (n=8) and 
      sextant biopsy specimens with isolated HGPIN without CaP (group A; n=11) and with 
      CaP (group B; n=14) on follow-up biopsy. Dual-color FISH assessing c-myc, 
      HER-2/neu, chromosome region 7q31 (D7S486), and corresponding chromosome 
      centromeres was performed. An amplification ratio (AR) for each marker centromere 
      was derived for each biopsy specimen, with AR ranges designated as no/low, 
      low-intermediate, and high. Also calculated for each marker were the percentage 
      of cells with marker amplification, hyperdiploidy, and monosomy. A composite 
      score for each biopsy specimen was calculated based on these parameters, with a 
      possible range of 0 to 15. The specific chromosomal oncogene CNAs were as 
      follows: for chromosome 7/7q31, 2 of 11 (18%) in group A and 6 of 14 (43%) in 
      group B; for chromosome 8/c-myc, 4 of 11 (36%) in group A and 9 of 13 (69%) in 
      group B; and for chromosome 17/HER-2/neu, 10 of 10 (100%) in group A and 13 of 14 
      (93%) in group B. The mean composite score was 0 for controls, 2.5 for group A, 
      and 4.7 for group B. Composite scores > or =4 for the 3 groups were 0 of 9 (0%) 
      for controls, 1 of 11 (12%) for group A, and 8 of 14 (57%) for group B. These 
      differences were statistically significant (P=0.015). One group A patient with a 
      high composite score (6) had atypical small glands on follow-up biopsy at <1 
      year. Chromosome/oncogene CNAs are uncommon in control patients, occurring with 
      increasing frequency and magnitude in patients with isolated HGPIN without and 
      with follow-up CaP. Chromosome/oncogene CNAs in HGPIN are mostly of the low to 
      intermediate level and display intercellular heterogeneity. HER-2/neu 
      amplification is common in HGPIN with and without follow-up CaP. Chromosome 7 and 
      8 aneusomy and 7q31 and c-myc amplification are greater in HGPIN with follow-up 
      CaP. Patients with isolated HGPIN and high composite score without follow-up CaP 
      are uncommon; these patients may have a small, unsampled CaP. Although patients 
      with HGPIN without CaP are more likely to have a low composite score, a subset of 
      patients with follow-up CaP have low composite score, suggesting (1) mutational 
      pathways independent of chromosomes 7, 8, and 17 and HER-2/neu, c-myc, and 
      chromosome region 7q31 CNAs; (2) CaP derived from an independent, unsampled focus 
      of HGPIN; or (3) CaP not derived from HGPIN.
FAU - Bastacky, Sheldon
AU  - Bastacky S
AD  - Department of Pathology, University of Pittsburgh School of Medicine, PA, USA.
FAU - Cieply, Kathleen
AU  - Cieply K
FAU - Sherer, Carol
AU  - Sherer C
FAU - Dhir, Rajiv
AU  - Dhir R
FAU - Epstein, Jonathan I
AU  - Epstein JI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism/*pathology
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Biopsy, Needle
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 7/genetics
MH  - DNA, Neoplasm/analysis
MH  - Follow-Up Studies
MH  - Gene Amplification
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prostate/metabolism/*pathology
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Intraepithelial Neoplasia/genetics/metabolism/*pathology
MH  - Prostatic Neoplasms/genetics/metabolism/*pathology
MH  - Proto-Oncogene Proteins c-myc/genetics/metabolism
MH  - Receptor, ErbB-2/genetics/metabolism
EDAT- 2004/03/16 05:00
MHDA- 2004/04/15 05:00
CRDT- 2004/03/16 05:00
PHST- 2004/03/16 05:00 [pubmed]
PHST- 2004/04/15 05:00 [medline]
PHST- 2004/03/16 05:00 [entrez]
AID - S004681770300652X [pii]
AID - 10.1016/j.humpath.2003.10.019 [doi]
PST - ppublish
SO  - Hum Pathol. 2004 Mar;35(3):281-9. doi: 10.1016/j.humpath.2003.10.019.